Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pindur

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Infusionstherapie Und Transfusionsmedizin|August 1, 1994
[Comparison of 2 6% middle-molecular hydroxyethyl starch solutions on elimination kinetics and flow characteristics of blood in volunteers]J Koscielny, F Jung, C Mrowietz, et al.
Klinische Wochenschrift|February 3, 1986
HTLV III antibodies and immunological alterations in hemophilia patientsE Seifried, G Pindur, H Stötter, et al.
Blut|July 1, 1984
Impaired natural killer cell function in hemophiliacs with or without continuous substitutionF Porzsolt, M Hauser, C Piper, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1990
[Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis]M Köhler, R Kotitschke, B Braun, et al.
Blut|December 1, 1988
In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standardsM Köhler, E Seifried, P Hellstern, et al.
Clinical Hemorheology and Microcirculation|December 8, 2010
Influence of bleeding on haemorheology and haemostasis in surgeryB Stephan, J F Schenk, G Pindur, et al.
Haemostasis|July 1, 1996
Highly substituted hydroxyethyl starch (HES200/0.62) leads to Type-I von Willebrand syndrome after repeated administrationJ Treib, A Haass, G Pindur, et al.
Seminars in Thrombosis and Hemostasis|May 18, 1999
Analysis and occurrence of adverse events with oral anticoagulant therapyJ F Schenk, S Mörsdorf, G Pindur, et al.
Neurology|March 4, 1998
Thunderclap headache caused by Erve virus?J Treib, G Dobler, A Haass, et al.
Haemostasis|September 1, 1996
Influence of low molecular weight hydroxyethyl starch (HES 40/0.5-0.55) on hemostasis and hemorheologyJ Treib, A Haass, G Pindur, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Infusionstherapie Und Transfusionsmedizin|August 1, 1994
[Comparison of 2 6% middle-molecular hydroxyethyl starch solutions on elimination kinetics and flow characteristics of blood in volunteers]J Koscielny, F Jung, C Mrowietz, et al.
Klinische Wochenschrift|February 3, 1986
HTLV III antibodies and immunological alterations in hemophilia patientsE Seifried, G Pindur, H Stötter, et al.
Blut|July 1, 1984
Impaired natural killer cell function in hemophiliacs with or without continuous substitutionF Porzsolt, M Hauser, C Piper, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1990
[Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis]M Köhler, R Kotitschke, B Braun, et al.
Blut|December 1, 1988
In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standardsM Köhler, E Seifried, P Hellstern, et al.
Clinical Hemorheology and Microcirculation|December 8, 2010
Influence of bleeding on haemorheology and haemostasis in surgeryB Stephan, J F Schenk, G Pindur, et al.
Haemostasis|July 1, 1996
Highly substituted hydroxyethyl starch (HES200/0.62) leads to Type-I von Willebrand syndrome after repeated administrationJ Treib, A Haass, G Pindur, et al.
Seminars in Thrombosis and Hemostasis|May 18, 1999
Analysis and occurrence of adverse events with oral anticoagulant therapyJ F Schenk, S Mörsdorf, G Pindur, et al.
Neurology|March 4, 1998
Thunderclap headache caused by Erve virus?J Treib, G Dobler, A Haass, et al.
Haemostasis|September 1, 1996
Influence of low molecular weight hydroxyethyl starch (HES 40/0.5-0.55) on hemostasis and hemorheologyJ Treib, A Haass, G Pindur, et al.
Pageof 10